Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
4/27/2026, 12:00:00 AM
On April 27, 2026, Eli Lilly announced a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion to expand its hematology pipeline. High importance is assigned based on the strategic value of the acquisition and an estimated price impact of over 10%.
Korean Translation
2026년 4월 27일 일라이 릴리의 아약스 테라퓨틱스 최대 23억 달러 규모 인수 계약 발표이며, 혈액학 파이프라인 확장 및 10% 이상의 주가 영향이 예상되어 높은 중요도로 분류함.
Related Recent Events
NVIDIA Corporation (NVDA) · Earnings Release
NVIDIA's Q1 fiscal 2027 earnings release is scheduled for May 20, 2026. Low importance assigned as the announcement of an earnings date typically results in ~1% price impact, scheduled.
5/20/2026, 12:00:00 AM
Hims & Hers Health Inc (HIMS) · Earnings Release
First quarter 2026 financial results and conference call on May 11, 2026, with high importance estimated due to potential market impact of earnings guidance, scheduled.
5/11/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Earnings Release
First quarter 2026 financial results on May 7, 2026, to be released after market close; significant price impact expected based on recent growth trends scheduled.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is expected to announce its Q1 2026 financial results scheduled. Scheduled earnings releases are key volatility events with an estimated 5% impact.
5/7/2026, 12:00:00 AM
Tempus AI Inc (TEM) · Earnings Release
First quarter 2026 financial results and business update scheduled for May 5, 2026; high impact from potential 10% price volatility expected.
5/5/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
BioNTech will report first-quarter 2026 financial results and provide a corporate update on 2026-05-05; given the sharp March 2026 volatility after guidance and leadership news, this update is likely to be closely watched and could move shares materially, expected.
5/5/2026, 12:00:00 AM